Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

被引：16

作者：

Chambers, Laura M. ^{[1
]}

Yao, Meng ^{[2
]}

Morton, Molly ^{[3
]}

Gruner, Morgan ^{[3
]}

Chichura, Anna ^{[3
]}

Horowitz, Max ^{[1
]}

Costales, Anthony B. ^{[4
]}

Rose, Peter G. ^{[1
]}

Michener, Chad M. ^{[1
]}

Debernardo, Robert ^{[1
]}

机构：

[1] Cleveland Clin, Div Gynecol Oncol, Obstet Gynecol Womens Hlth Inst, Desk A81,9500 Euclid Ave, Cleveland, OH 44195 USA

[2] Cleveland Clin, Dept Qualitat Hlth Sci, Cleveland, OH 44195 USA

[3] Cleveland Clin, Obstet Gynecol Womens Hlth Inst, Desk A81,9500, Cleveland, OH 44106 USA

[4] Baylor Coll Med, Dept Gynecol Oncol, Houston, TX 77030 USA

来源：

GYNECOLOGIC ONCOLOGY | 2021年 / 161卷 / 02期

关键词：

Epithelial ovarian cancer; Hyperthermic intraperitoneal chemotherapy; Recurrence; PACLITAXEL; CISPLATIN; CARCINOMA; SURVIVAL;

D O I：

10.1016/j.ygyno.2021.01.039

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objective(s). To identify recurrence patterns and outcomes in women with advanced or recurrent epithelial ovarian cancer (EOC) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Methods. This is an IRB-approved single-institution cohort study of women who underwent CRS+HIPEC for advanced or recurrent EOC followed in a prospective registry from 1/12/2014-3/1/2020. Recurrence locations were defined as pelvic, upper abdominal (UA) and/or extra-peritoneal (EP). Univariate analysis assessed associations between recurrence location, progression-free survival (PFS), and overall survival (OS). Results. In total, 92 women with EOC underwent interval (56.5%; n=52) or recurrent CRS+HIPEC (43.5%; n= 40). For interval CRS+HIPEC, recurrence locations were pelvic in 50.0% (n=15), UA in 23.3% (n=7) and EP in 56.7% (n=17); 40.0% (n=12) were EP alone. Similarly, for recurrent CRS+HIPEC, recurrence locations were pelvic (22.5%, n=9), UA (5.0%, n=2) and EP (60.0%, n=24); 66.7% (n=20) were EP alone. For both interval and recurrent CRS+HIPEC, median PFS was 10.5 vs. 13.0 months for pelvic and UA vs. EP only recurrences (p=0.02). Similarly, median OS was 29.2 months for pelvic and UA and not reached for EP only (p=0.05). For interval CRS+HIPEC, there was no difference in median PFS (10.6 vs. 11.7 months, p=0.68) and OS (27.1 vs. 24.8 months, p=0.96) for pelvic and UA vs EP alone. However, for recurrent CRS+HIPEC, pelvic and UA sites of recurrence were associated with reduced PFS (10.0 vs. 18.1 months, p=0.03) and OS (33.6 months vs. not reached, p= 0.02) vs. EP only. Conclusions. In women with advanced or recurrent EOC undergoing CRS+HIPEC, one-half of patients experience their first recurrence outside of the peritoneal cavity. Providers must be aware of the risk of EP failure in patients treated with CRS+HIPEC. (c) 2021 Elsevier Inc. All rights reserved.

引用

页码：389 / 395

页数：7

共 24 条

[1] Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer [J].

Alberts, DS ;

Liu, PY ;

Hannigan, EV ;

OToole, R ;

Williams, SD ;

Young, JA ;

Franklin, EW ;

ClarkePearson, DL ;

Malviya, VK ;

DuBeshter, B ;

Adelson, MD ;

Hoskins, WJ .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (26) :1950-1955

[2] Treatment of Microscopic Disease with Hyperthermic Intraoperative Intraperitoneal Chemotherapy After Complete Cytoreduction Improves Disease-Free Survival in Patients with Stage IIIC/IV Ovarian Cancer [J].

Antonio Cascales-Campos, Pedro ;

Gil, J. ;

Gil, E. ;

Feliciangeli, E. ;

Gonzalez-Gil, A. ;

Parrilla, J. J. ;

Parrilla, P. .

ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (07) :2383-2389

[3] Intraperitoneal cisplatin and paclitaxel in ovarian cancer [J].

Armstrong, DK ;

Bundy, B ;

Wenzel, L ;

Huang, HQ ;

Baergen, R ;

Lele, S ;

Copeland, LJ ;

Walker, JL ;

Burger, RA .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) :34-43

[4]

Armstrong DK., 2020, NCCN clinical practice guidelines in oncology (NCCN Guidelines1) ovarian cancer including Fallopian tube cancer and primary peritoneal cancer. version

[5] Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery [J].

Bae, Jeong Hoon ;

Lee, Joon Mo ;

Ryu, Ki Sung ;

Lee, Yong Seok ;

Park, Yong Gyu ;

Hur, Soo Young ;

Ahn, Woong Shik ;

Namkoong, Seong Eun .

GYNECOLOGIC ONCOLOGY, 2007, 106 (01) :193-200

[6] Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: A French multicentre retrospective cohort study of 566 patients [J].

Bakrin, N. ;

Bereder, J. M. ;

Decullier, E. ;

Classe, J. M. ;

Msika, S. ;

Lorimier, G. ;

Abboud, K. ;

Meeus, P. ;

Ferron, G. ;

Quenet, F. ;

Marchal, F. ;

Gouy, S. ;

Morice, P. ;

Pomel, C. ;

Pocard, M. ;

Guyon, F. ;

Porcheron, J. ;

Glehen, O. .

EJSO, 2013, 39 (12) :1435-1443

[7] Incidence and predictors of peritoneal metastases of gynecological origin: a population-based study in the Netherlands [J].

Burg, Lara ;

Timmermans, Maite ;

van der Aa, Maaike ;

Boll, Dorry ;

Rovers, Koen ;

de Hingh, Ignace ;

van Altena, Anne .

JOURNAL OF GYNECOLOGIC ONCOLOGY, 2020, 31 (05) :1-12

[8] Effect of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on relapse pattern in primary epithelial ovarian cancer: a propensity score based case-control study [J].

Ceresoli, Marco ;

Verrengia, Apollonia ;

Montori, Giulia ;

Busci, Luisa ;

Coccolini, Federico ;

Ansaloni, Luca ;

Frigerio, Luigi .

JOURNAL OF GYNECOLOGIC ONCOLOGY, 2018, 29 (03)

[9] A guide to establishing a hyperthermic intraperitoneal chemotherapy program in gynecologic oncology [J].

Chambers, Laura M. ;

Costales, Anthony B. ;

Crean-Tate, Katie ;

Kuznicki, Michelle ;

Morton, Molly ;

Horowitz, Max ;

Jagielo, Tiffany ;

Rose, Peter G. ;

Michener, Chad ;

Vargas, Roberto ;

Debernardo, Robert .

GYNECOLOGIC ONCOLOGY, 2020, 158 (03) :794-802

[10] Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy [J].

Esselen, Katharine M. ;

Rodriguez, Noah ;

Growdon, Whitfield ;

Krasner, Carolyn ;

Horowitz, Neil S. ;

Campos, Susana .

GYNECOLOGIC ONCOLOGY, 2012, 127 (01) :51-54

← 1 2 3 →